HER-2在胃癌和结直肠癌中的抑制作用：切实成就、新进展及未来展望
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.
作者信息
Fanotto Valentina, Ongaro Elena, Rihawi Karim, Avallone Antonio, Silvestris Nicola, Fornaro Lorenzo, Vasile Enrico, Antonuzzo Lorenzo, Leone Francesco, Rosati Gerardo, Giuliani Francesco, Bordonaro Roberto, Scartozzi Mario, De Maglio Giovanna, Negri Francesca V, Fasola Gianpiero, Aprile Giuseppe
机构信息
Department of Oncology, University and General Hospital, Udine, Italy.
Department of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
出版信息
Oncotarget. 2016 Oct 18;7(42):69060-69074. doi: 10.18632/oncotarget.11264.
HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.
HER-2（ErbB-2、c-erbB2或Her2/neu）是HER家族的一员，直接参与多种人类癌症的发病机制和进展；因此，它也常被视为不良预后因素。继抗HER-2治疗对乳腺癌患者产生革命性影响之后，HER-2及其阻断作用在其他肿瘤类型中，包括胃腺癌和结肠腺癌，也得到了广泛评估。本综述的目的是回顾在胃癌和结直肠癌中使用HER-2抑制剂所取得的重要成果，并讨论HER-2作为这些恶性肿瘤预后和预测因素的最新情况。
Zotero 插件